

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanxi Central Pharmaceutical International Limited

(In Liquidation)

正中藥業國際有限公司 *

(清盤中)

(incorporated in Bermuda with limited liability)

(Stock Code: 327)

ANNOUNCEMENT

The Stock Exchange has announced that with effect from 9:30am on 6 April 2005, the listing of the shares of the Company will be cancelled in accordance with the Delisting Procedures.

By the end of the Deadline mentioned below, the Company has failed to submit a valid proposal for resumption. Therefore, the Stock Exchange will cancel the listing of the Company's shares in accordance with the Delisting Procedures.

Trading in the shares of the Company has been suspended since 25 July 2003.

CANCELLATION OF LISTING

The Stock Exchange of Hong Kong Limited (the "Stock Exchange") has announced that the listing of the shares of Shanxi Central Pharmaceutical International Limited (In Liquidation) (正中藥業國際有限公司 *) (清盤中) (the "Company") will be cancelled with effect from 9:30am on 6 April 2005 in accordance with the delisting procedures stipulated in Practice Note 17 of the Listing Rules (the "Delisting Procedures"). Practice Note 17 to the rules governing the listing of securities on the Stock Exchange (the "Listing Rules") formalises the procedures to be adopted to delist long-suspended companies.

Dealings in the Company's shares have been suspended since 25 July 2003. Accordingly, dealings in the Company's shares have effectively been suspended for over 20 months.

The Company was put into the third stage of the Delisting Procedures on 10 September 2004. Pursuant to the Delisting Procedures, at the end of the third stage which in the case of the Company was 9 March 2005 (the "Deadline"), where no valid proposals have been received for resumption, the listing of the Company's shares will be cancelled. Following the suspension in trading in the Company's shares and before the Deadline, a resumption proposal (the "Proposal") was submitted to the Stock Exchange on 7 June 2004. After reviewing the Proposal, the Listing Division decided that the resumption proposal was not viable.

Pursuant to paragraph 3.1 of Practice Note 17, the Joint and Several Provisional Liquidators of the Company hereby announce the cancellation of the listing of the Company's shares with effect from 6 April 2005.

Shareholders of the Company who have any queries about the implications of the delisting should obtain appropriate professional advice.

As at the date of this announcement, the board of directors of the Company only consists of Mr. KO Siu Shing, Patrick, an independent non-executive director.

Trading in the shares of the Company has been suspended since 25 July 2003.

Please note that this announcement has only been released on the Teletex System of The Stock Exchange of Hong Kong Limited and has not been published in the newspapers as required by the Listing Rules due to the liquidity problems of the Company.

For and on behalf of
Shanxi Central Pharmaceutical International Limited
(In Liquidation)
Lai Kar Yan (Derek)
Joint and Several Provisional Liquidator

Hong Kong, 4 April 2005

*for identification only